Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05872256 · ClinicalTrials.gov registry record · Phase 4
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
A Phase 4 study of Scalp Psoriasis, sponsored by Dermatology Consulting Services, P.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05872256 is a Phase 4 study of Scalp Psoriasis that has completed, run by Dermatology Consulting Services, P. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05872256, a Phase 4 study of Scalp Psoriasis, has completed, sponsored by Dermatology Consulting Services, P.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.
Conditions Studied
Interventions
- DRUG 0.045% Tazarotene/0.01% Halobetasol Lotion
Study Locations (1)
North Carolina
- Dermatology Consulting Services, PLLC - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05872256
The ClinicalTrials.gov registry entry for NCT05872256 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dermatology Consulting Services, P, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scalp Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which 0.045% Tazarotene/0.01% Halobetasol Lotion is the first listed.
NCT05872256 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05872256 about?
NCT05872256 is a clinical study titled "A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis". The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp i...
What is the current status of trial NCT05872256?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-06-01. Estimated completion is 2023-11-13.
What conditions does trial NCT05872256 study?
This clinical trial studies the following conditions: Scalp Psoriasis.
What interventions are being tested in trial NCT05872256?
The interventions under investigation include: 0.045% Tazarotene/0.01% Halobetasol Lotion (DRUG).
Who is sponsoring clinical trial NCT05872256?
This trial is sponsored by Dermatology Consulting Services, P, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05872256 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scalp Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.